Abstract
While conventional wisdom initially postulated that PD-L1 serves as the inert ligand for PD-1, an emerging body of literature suggests that PD-L1 has cell-intrinsic functions in immune and cancer cells. In line with these studies, here we show that engagement of PD-L1 via cellular ligands or agonistic antibodies, including those used in the clinic, potently inhibits the type I interferon pathway in cancer cells. Hampered type I interferon responses in PD-L1–expressing cancer cells resulted in enhanced efficacy of oncolytic viruses in vitro and in vivo. Consistently, PD-L1 expression marked tumor explants from cancer patients that were best infected by oncolytic viruses. Mechanistically, PD-L1 promoted a metabolic shift characterized by enhanced glycolysis rate that resulted in increased lactate production. In turn, lactate inhibited type I IFN responses. In addition to adding mechanistic insight into PD-L1 intrinsic function, our results will also help guide the numerous ongoing efforts to combine PD-L1 antibodies with oncolytic virotherapy in clinical trials.
Funding Information
  • Canadian Institutes of Health Research
  • Ride for Dad
  • Cancer Research Society
  • Charles Best Canada Graduate Scholarships Doctoral
  • Ontario Graduate Scholarship
  • BioCanRX
  • Canadian Allergy, Asthma, and Immunology Foundation
  • University of Ottawa Heart Institute
  • Schulich Leader Scholarship
  • University of Ottawa
  • Natural Sciences and Engineering Research Council of Canada
  • Taggart-Parkes Fellowship
  • CI3 scholarship
  • Vanier Canada
  • Canadian Cancer Society Research Institute
  • Terry Fox Research Institute
  • Canadian Fund for Innovation
  • Terry Fox Foundation
  • Prostate Cancer Canada